amyloid Archives -

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

https://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/

Double resignation over Aduhelm approval depletes FDA’s CNS adcomm

https://pharmaphorum.com/news/double-resignation-over-aduhelm-approval-depletes-fdas-cns-adcomm/

Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab

https://pharmaphorum.com/news/jubilation-at-biogen-as-fda-says-yes-to-aducanumab/

Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?

https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/

FDA panel unimpressed with data for Alzheimer’s drug aducanumab

https://pharmaphorum.com/news/fda-sceptical-on-biogen-eisai-data-for-alzheimers-drug-aducanumab/

Trials and tribulations in Biogen’s Alzheimer’s drug reviews

https://pharmaphorum.com/news/trials-and-tribulations-in-biogens-alzheimers-drug-reviews/

Surprise! Biogen says Alzheimer’s drug works after all and will be filed

https://pharmaphorum.com/news/surprise-biogen-says-alzheimers-drug-works-after-all-and-will-be-filed/

A bright future for CNS and Alzheimer’s?

https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/

Biogen drug shows potential in Alzheimer’s

https://pharmaphorum.com/news/biogen-drug/

Search